Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. Whereas chickenpox infections are normally mild but common among children, HZ infections are common among elderly people and can give rise to post-herpetic neuralgia (PHN), a severe and painful complication.; This review aimed to summarize the literature available on the cost effectiveness of HZ vaccination and to summarize key issues for decision makers to consider when deciding on the reimbursement of HZ vaccination.; We conducted a literature search of the databases PubMed and EMBASE using EndNote X4 from Thomson Reuters. Therefore, we investigated Korean physicians’ attitudes toward the HZ vaccine and factors that might impact physician recommendations, in an effort to increase the vaccine coverage rate in eligible individuals. HZ vaccine has been first approved for adults aged 60 years and above, and recently approved for 50 years and above. The “moving wall” represents the time period between the last issue available in JSTOR and the most recently published issue of a journal. It is essential that authors present these choices transparently so that users of economic evaluations understand the implications of such choices and the direction in which the results of the analysis were conducted. SYNTHESIS: The Szucs systematic review presented a thorough methodological assessment of the relevant literature.
If you have been exposed to chickenpox, the varicella-zoster virus can reactivate later in life. vaccine recipients aged >or=60 years, use of the zoster vaccine was projected to eliminate 75,548-88,928HZ cases and over 20,000 PHN cases. Cost assumptions, discount rate assumptions, assumptions about vaccine efficacy and waning and epidemiological assumptions drove variation in the outcomes. €40,984 per QALY gained). The aim of this review is to summarize and synthesize the literature on cost-effectiveness of routine vaccination against HZ and to identify those input parameters that are crucial in determining cost-effectiveness outcomes. Few studies showed that vaccination cost-effectiveness was higher than this threshold, and only under conservative assumptions. About 1 out of 3 people will get shingles in their lifetime.